Search for: "Watson Pharmaceuticals, Inc."
Results 161 - 180
of 225
Sorted by Relevance
|
Sort by Date
13 Jan 2010, 3:00 am
Cobrek Pharmaceuticals, Inc (Patent Docs) Nexium (Esomeprazole) – US: Teva drops patent challenge following settlement agreement with AstraZeneca over Nexium (IP Factor) (GenericsWeb) Nuvigil (Armodafinil) - US: Mylan confirms first-to-file patent challenge relating to sleep-disorder drug (SmartBrief) Nuvigil (Armodafinil) - US: Cephalon sues Watson for patent infringement following Para IV challenge (Patent Docs) (GenericsWeb) (Patentcircle) Tasigna (Nilotinib) -… [read post]
28 Jun 2011, 6:30 am
In addition, following the submission of one of the proposals (to Watson Pharmaceuticals, Inc.), the company announced a plan to bring a declassification proposal to a vote at its 2011 annual meeting. [read post]
10 Jun 2013, 9:30 pm
Watson Pharmaceuticals, Inc, a case raising the question of the legality of these agreements. [read post]
15 Sep 2010, 2:15 am
Watson Pharmaceuticals, Inc., D2010-0800 (WIPO August 31, 2010). [read post]
15 Nov 2012, 7:50 am
Watson of the U.S. [read post]
10 Apr 2012, 1:15 pm
The Zarah and Vestura oral contraceptives are made by Watson Pharmaceuticals; and Loryna, a generic version of YAZ, and Syeda, a generic version of Yasmin. [read post]
22 Mar 2011, 4:21 pm
General New IP resource for Pharma, Biotech and Chem – Compulsory licences, comparing national requirements (IP Think Tank) WIPO and India partner to protect traditional knowledge from misappropriation (WIPO) UN Rapporteur for the Right to Health asked to intervene in the TPP negotiation (KEI) Patents and doctors, and the USTR TPP text (KEI) Biotech industry losing interest in the therapeutic potential of RNAi (Patent Docs) India: The curious case of the ‘data exclusivity’ volte… [read post]
3 Nov 2010, 1:21 am
No – discussion of patent-eligibility standards for genes (Patent Baristas) US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs) US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog) US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog) Products Botox (Botulinum) – EU: General Court upholds opposition to BOTUMAX Community… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
6 Jul 2011, 2:21 am
Biopet Vet Lab, Inc., et. al. [read post]
8 Dec 2007, 11:00 am
: (IP Think Tank), WIPO - Idris gets paid out to leave early: (IAM), (Patent Prospector), Deutsche Grammophon ditches DRM: (ArsTechnica)PharmaFDA revisits NCE exclusivity for enantiomers: (Arnall Golden & Gregory), Accupril (Quinapril) - Judge finds against Teva and holds Warner-Lambert patent enabled: (IPLaw360), (OrangeBookBlog), Altace / Tritace / Ramace (Ramipril) - King Pharmaceuticals loses CAFC rehearing bid: (IPLaw360), … [read post]
8 Feb 2017, 3:09 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
6 Apr 2017, 1:35 pm
Mylan, Inc., No. 15-1113(Fed. [read post]
16 Jan 2017, 5:44 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
27 Jul 2011, 1:01 am
Paddock Laboratories, Inc. [read post]
5 Aug 2009, 5:35 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: America’s Affordable Health Choices Act : House Energy & Commerce Committee OKs 12-year data exclusivity for biotech drugs (Patent Baristas) (Patent Docs) (FDA Law Blog) (PatentlyBIOtech) (GenericsWeb) General Pharmaceutical patent settlements under fire on both sides of the Atlantic (GenericsWeb)… [read post]
22 Feb 2012, 7:37 am
Watson Pharmaceuticals, Inc., D2010-0800 (WIPO August 31, 2010) (A company “can readily protect itself by securing a clear written agreement. [read post]
20 Jul 2011, 4:04 am
: Supreme Court hearing Human Genome Sciences Inc v Eli Lilly and Company (IPKat) Nexium (Esomeprazole) – UK: EWHC: Ranbaxy wins declaration of non-infringement: Ranbaxy v AstraZeneca (IPKat) Olanzapine – Spain: Supreme Court hands down landmark judgment on doctrine of equivalents and TRIPS (Kluwer Patent Blog) OxyContin (Oxycodone) – US: Purdue files patent infringement suit against Sandoz in response to Para IV certification (Patent Docs) Prevacid (Lansoprazole) –… [read post]
1 May 2012, 6:49 pm
Watson Pharmaceuticals, Inc., (a/k/a In re: Androgel Antitrust Litigation) addressing the prominent antitrust/patent/health care law issue of the validity of so-called "reverse payment" or "pay for delay" settlements between pharmaceutical patent holders (i.e. name brand drug makers) and competing drug makers seeking to market generic alternatives. [read post]
15 Feb 2011, 5:26 pm
(FDA Law Blog) Diovan (Vasartan) – France: Novartis v Actavis – preliminary injunction for Valsartan confirmed (The SPC Blog) Diovan HTC (Valsartan) – Belgium: Antwerp Court of Appeal stops infringement of Valsartan/HCTZ SPC based on patent claiming Valsartan alone: Novartis v Teva (The SPC Blog) Lescol (Fluvastatin) – US: Novartis files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (GenericsWeb) Mucinex (Guaifenesin) – US:… [read post]
